1. Multilocular Cystic Renal Cell Carcinoma
- Author
-
Rodolfo Montironi, Lucia C. Japp, Enrico Bollito, Ferran Algaba, Ana Romero, Ana L.C. Gentili, Ricardo Drut, Antonio Lopez-Beltran, Maria J. Requena-Tapias, Tomayoshi Hayashi, Athanase Billis, Ines deTorres, Sueli Suzigan, and Paulo S.P. Fonseca
- Subjects
medicine.medical_specialty ,Kidney ,business.industry ,General Medicine ,Multilocular Cystic Renal Cell Carcinoma ,medicine.disease ,Surgery ,Clear cell renal cell carcinoma ,medicine.anatomical_structure ,Cohort ,medicine ,Neoplasm ,Clinical significance ,Radiology ,Stage (cooking) ,business ,Survival rate - Abstract
The 2004 World Health Organization (WHO) classification of kidney tumors recognizes multilocular cystic renal cell carcinoma (MCRCC) as a rare variant of clear cell renal cell carcinoma with a good prognosis. Available information on its clinical significance is limited. The study cohort included 45 MCRCC cases classified according to 2004 WHO criteria obtained through a multi-institutional international search. Most patients had unilateral MCRCC with no side predominance that was found incidentally; 62% were men, but women had tumors at an earlier age ( P = .385). MCRCC occurred slightly more often in men than in women (1.7:1). At diagnosis, 82% of patients had stage T1 and 16%, stage T2; 1 patient had stage T3. The Fuhrman grade was 1 (62%) or 2 (38%), with smaller tumors (≤4 cm) most likely Fuhrman grade 1 ( P = .911). All 45 patients were alive with no evidence of disease at mean follow-up of 66.1 months, confirming an extremely good prognosis after surgery and a 5-year disease-specific survival rate of 100%. To rename this tumor as multilocular cystic renal cell neoplasm of low malignant potential might help urologists approach the patients conservatively.
- Published
- 2006
- Full Text
- View/download PDF